- Home
- CRBP vs COYA Comparison
CRBP vs COYA Comparison
Compare CRBP & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- COYA
- Stock Information
- Founded
- CRBP 2009
- COYA 2020
- Country
- CRBP United States
- COYA United States
- Employees
- CRBP N/A
- COYA N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- COYA Health Care
- Exchange
- CRBP Nasdaq
- COYA Nasdaq
- Market Cap
- CRBP 110.3M
- COYA 107.0M
- IPO Year
- CRBP N/A
- COYA 2022
- Fundamental
- Price
- CRBP $9.79
- COYA $6.86
- Analyst Decision
- CRBP Strong Buy
- COYA Strong Buy
- Analyst Count
- CRBP 10
- COYA 4
- Target Price
- CRBP $53.22
- COYA $16.50
- AVG Volume (30 Days)
- CRBP 107.9K
- COYA 52.8K
- Earning Date
- CRBP 08-05-2025
- COYA 08-12-2025
- Dividend Yield
- CRBP N/A
- COYA N/A
- EPS Growth
- CRBP N/A
- COYA N/A
- EPS
- CRBP N/A
- COYA N/A
- Revenue
- CRBP N/A
- COYA $423,452.00
- Revenue This Year
- CRBP N/A
- COYA $40.52
- Revenue Next Year
- CRBP $270.04
- COYA N/A
- P/E Ratio
- CRBP N/A
- COYA N/A
- Revenue Growth
- CRBP N/A
- COYA N/A
- 52 Week Low
- CRBP $4.64
- COYA $4.65
- 52 Week High
- CRBP $61.89
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- CRBP 62.32
- COYA 62.90
- Support Level
- CRBP $8.88
- COYA $5.86
- Resistance Level
- CRBP $9.59
- COYA $6.28
- Average True Range (ATR)
- CRBP 0.59
- COYA 0.40
- MACD
- CRBP 0.03
- COYA 0.05
- Stochastic Oscillator
- CRBP 78.45
- COYA 97.67
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.